Lifestyle Drugs Market By Disease 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Lifestyle Drugs Market
Lifestyle Drugs Market: By Disease (Erectile dysfunction, Balding, Weight loss, Cosmetic, Focus & Energy, Birth Control, Smoking Cessation) & By Region-Forecast (2016-2021)
Report Code : HCR 0290
Updated Date: 04 January, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Lifestyle Drugs Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Lifestyle Drugs Market– Market Forces
   4.1. Drivers
      4.1.1. Growing population with lifestyle related health issues
      4.1.2. Increasing spending for fitness and health
   4.2. Restraints
   4.3. Opportunities
      4.3.1. Emerging economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Lifestyle Drugs Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Lifestyle Drugs Market, By Disease
   6.1. Erectile dysfunction
   6.2. Balding
   6.3. Weight loss
   6.4. Cosmetic
   6.5. Focus & Energy
   6.6. Birth Control
   6.7. Smoking Cessation
   6.8. Others
7. Lifestyle Drugs Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Lifestyle Drugs – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   9.1. Pfizer Inc.
   9.2. Eli Lily
   9.3. Teva Pharmaceuticals
   9.4. Biocon Ltd.
   9.5. Mylan pharmaceuticals
   9.6. GlaxoSmithKline
   9.7. McNeil
   9.8. Johnson & Johnson
   9.9. Merck & Co. Inc.
   9.10. Dr. Reddy’s Laboratories
   9.11. Zydus Cadila
   9.12. Cipla
   9.13. Sun Pharmaceuticals
   9.14. Nicholas Piramal
   9.15. Alembic
   9.16. Proctor & Gamble
   9.17. Astrazeneca
   9.18. Novo Nordisk
   9.19. Amgen
   9.20. Lupin
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix

   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
Lifestyle style drugs are defined as medicines which are used to treat diseases arise due to lifestyle illnesses or habits such as smoking, alcoholism or unhealthy diet habits. Lifestyle medicines are aimed at improving person’s quality of life by treating conditions that are not lethal or non-painful which include baldness, wrinkles, impotence, acne, weight loss, insomnia, and others. Over the past few years, lifestyle drugs have become commercially attractive and one of the most dynamic industries across the globe. Growing popularity of lifestyle drugs is primarily driven by attributors such as increase in stamina, memory, concentration and energy level which are of prime need among youth and middle aged population owing to stressful and unhealthy lifestyle.

Lifestyle Drugs Market

Geographically North America dominated global lifestyle drugs market, due to higher awareness about lifestyle related disease, better healthcare infrastructure and better spending power of its citizens. North America was followed by Europe and Asia-Pacific as second and third largest market of lifestyle drugs. Asia Pacific is projected to have fastest growth, owing to rapidly changing lifestyle of the people in the region due to industrialization and developing health care coupled with increasing awareness in developing nations such as China, and India in this region. Among all the drug class weight loss related drugs is expected to have fastest growth during the period of study.

This report identifies the global lifestyle drugs market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global lifestyle drugs market.

This report segments global lifestyle drugs market on the basis of disease addressed and regional market as follows:
  • Lifestyle Drugs Market, By Disease: Erectile dysfunction, Balding, Weight loss, Cosmetic, Focus & Energy, Birth Control, Smoking Cessation, and Others
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the lifestyle drugs market. Some of the major companies’ profiles in detail are as follows:
  • Mylan pharmaceuticals
  • GlaxoSmithKline
  • McNeil
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Dr. Reddy’s Laboratories
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports